Recordati Board of Directors approves 2011 interim dividend of € 0.20 per share

Milan, 14 November 2011 – The Board of Directors of Recordati S.p.A. resolved to distribute an interim dividend relating to the financial year 2011 amounting to € 0.20 (before withholding tax) on each outstanding share, excluding shares in treasury stock. The interim dividend will be paid as from November 24, 2011 on coupon No. 8 to be presented on November 21, 2011.

The opinion of the independent auditor KPMG S.p.A. required by Article 2433-bis of the Italian Civil Code was released today.

The financial statements of Recordati S.p.A. as at 30 September 2011 and the Directors’ Report, on the base of which the Board of Directors resolved to distribute the abovementioned interim dividend, are available at the Company’s registered offices and Borsa Italiana S.p.A., as well as being published on the Company’s web site www.recordati.com.  The Independent Auditor’s opinion on the distribution of the interim dividend is also available at the Company’s registered offices as per article 2433-bis of the Italian Civil Code.

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271),with a total staff of over 2,800, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the new markets of Central and Eastern Europe.  A European field force of around 1,400 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati’s current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations.  Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases.  Consolidated revenue for 2010 was € 728.1 million, operating income was € 154.8 million and net income was € 108.6 million.

For further information:

Recordati website:  www.recordati.com

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company’s control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company’s activities and are not intended to indicate the advisability of administering any product in any particular instance.